Articles related to LEUKEMIA

In the phase III GAIA–CLL13 study, researchers investigated time-limited treatment options for fit patients with chronic lymphocytic leukemia (CLL) and a low burden of coexisting conditions. The study compared the efficacy of chemoimmunotherapy with venetoclax-obinutuzumab, both with and without ibrutinib. The results showed that the venetoclax-based regimens were superior to chemoimmunotherapy in terms of achieving undetectable minimal residual disease and longer progression-free survival (PFS). The percentages of patients with undetectable minimal residual disease were remarkably high, with 86.5% in the venetoclax-obinutuzumab group and 92.2% in the venetoclax-obinutuzumab-ibrutinib group, among the highest reported in first-line treatment for CLL. The study confirmed the significant prognostic value of undetectable minimal residual disease at the end of time-limited treatment, as it translated into superior PFS. The study emphasized the need for treatment options for fit CLL patients with normal renal function, as data from prospective, randomized clinical studies evaluating the safety and efficacy of venetoclax-obinutuzumab in this specific patient population were lacking. The study demonstrated that the venetoclax-obinutuzumab-ibrutinib combination had a higher incidence of tumor lysis syndrome compared to venetoclax-ibrutinib, likely due to the simultaneous administration of obinutuzumab with ibrutinib, leading to rapid depletion of CLL cells. The findings highlight the importance of continuing […]

Nutritional challenges are common in older adults with acute leukemia (AML/MDS), and can have a significant impact on their quality of life and treatment outcomes. These challenges can be caused by a variety of factors, including the disease itself, its treatment, and the normal aging process. Some of the most common nutritional challenges in older adults with AML/MDS include appetite loss, weight loss, diarrhea, constipation, and mouth sores; physicians can provide nutritional interventions to help address these challenges and improve the quality of life for older adults with AML/MDS. These interventions may include nutrition counseling, meal planning, supplementation, and enteral nutrition.

This study compared the efficacy and safety of four different treatment regimens for patients with chronic lymphocytic leukemia (CLL): chemoimmunotherapy, venetoclax-rituximab, venetoclax-obinutuzumab, and venetoclax-obinutuzumab-ibrutinib. The results showed that the venetoclax-obinutuzumab-ibrutinib regimen was the most effective, with significantly higher rates of undetectable minimal residual disease (MRD) and progression-free survival (PFS) at 15 months and 3 years, respectively, compared to the other regimens. The venetoclax-obinutuzumab regimen was also effective, with significantly higher rates of undetectable MRD at 15 months compared to chemoimmunotherapy. However, there was no significant difference in PFS at 3 years between the venetoclax-obinutuzumab and chemoimmunotherapy regimens. The venetoclax-rituximab regimen was the least effective, with no significant difference in undetectable MRD or PFS at 15 months or 3 years compared to chemoimmunotherapy. The most common adverse events were infections, which were more common with chemoimmunotherapy and venetoclax-obinutuzumab-ibrutinib than with the other regimens.

Advancing kidney health. Nanoscience. Bioanalytics. Biomaterials. Fighting pediatric leukemias. What’s the common thread? They describe the areas of research focus for four electees to AAAS this year.

As reported at the at the AACR Annual Meeting 2023, the combination of Ianalumab and ibrutinib showed promising results in treating chronic lymphocytic leukemia (CLL) in a phase 1b, dose-escalation and expansion trial. Ianalumab, an anti-BAFF-R monoclonal antibody, works by inhibiting B-cell differentiation, proliferation, and survival, and depleting B-cells through antibody-dependent cellular cytotoxicity within the tumor microenvironment. The trial treated 15 patients with CLL who were already receiving ibrutinib with different doses of Ianalumab for 6 cycles, with patients continuing the combination up to cycle 8 if they showed evidence of disease, and then followed up every 3 months for 2 years. The ORR at cycle 9 or before treatment discontinuation was 56.7%, with a complete response (CR) rate of 37.8%. Patients who were in their first line of treatment showed better outcomes than patients who had relapsed or refractory disease, with the ORR for previously-untreated patients being 81.8% with a CR of 54.5% and a CR + CRi of 63.6%. Additionally, 45.9% of patients achieved undetectable minimal residual disease (uMRD) in blood or bone marrow by cycle 9 of treatment, including 63.6% of patients in their first line of therapy and 38.5% of patients with relapsed/refractory disease. There were […]

In patients with R/R MDS/AML, the combination ipilimumab + decitabine (IPI + DEC) therapy shows a favorable safety profile and significant therapeutic activity that doesn’t seem to require T cell-mediated alloreactivity. Potential transplant candidates may find that IPI + DEC therapy acts as a less strenuous transition to transplant. Future research is necessary to determine logical IPI-based treatment plans that can provide persistent responses without causing significant immune damage.